Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report)’s share price was up 6.2% on Tuesday . The stock traded as high as $0.99 and last traded at $0.91. Approximately 916,008 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 1,172,326 shares. The stock had previously closed at $0.85.
Dermata Therapeutics Trading Up 6.2 %
The business’s 50-day simple moving average is $0.99 and its 200-day simple moving average is $1.16. The company has a market cap of $5.48 million, a PE ratio of -0.06 and a beta of 0.59.
About Dermata Therapeutics
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Read More
- Five stocks we like better than Dermata Therapeutics
- What Investors Need to Know to Beat the Market
- 3 Mid-Cap Medical Stocks Outperforming the Market
- Breakout Stocks: What They Are and How to Identify Them
- The Top-Ranked Insider Buys From April by Market Cap
- Want to Profit on the Downtrend? Downtrends, Explained.
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
